Syndax Pharmaceuticals
SNDX
230 hedge funds and large institutions have $2.1B invested in Syndax Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 80 reducing their positions, and 27 closing their positions.
108% more call options, than puts
Call options by funds: $30M | Put options by funds: $14.4M
35% more capital invested
Capital invested by funds: $1.56B → $2.1B (+$544M)
26% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 27
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
1% more funds holding
Funds holding: 227 → 230 (+3)
4% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 80
2.37% less ownership
Funds ownership: 117.38% → 115.01% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$40.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$17.7M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$13.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$51M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$30.4M |
| 3 |
Millennium Management
New York
|
-$17.3M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$16.7M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$16.7M |
SNDX Hedge Fund Activity: Q4 2025 in Review
230 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2025, worth a combined $2.1B — up 35% from $1.56B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new SNDX positions and 27 closed out — a net gain of 7 holders — while 83 added to existing stakes and 80 trimmed.
The largest buyer was Hood River Capital Management, opening a new position worth an estimated $40.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $51M sold.
- 230 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2025, up from 227 in Q3 2025.
- Funds reported $2.1B of Syndax Pharmaceuticals stock for Q4 2025, up 35% quarter-over-quarter.
- 34 funds opened new Syndax Pharmaceuticals positions in Q4 2025 and 27 closed out, a net change of +7 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2025 was Hood River Capital Management, an estimated $40.4M added.
- The largest Syndax Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $51M sold.
Based on aggregated 13F filings for Q4 2025.